ASLAN Pharmaceuticals (Nasdaq: ASLN) has screened the first patient in its Phase 2b dose-ranging clinical study of eblasakimab in adults with moderate-to-severe atopic dermatitis.
For more information, please refer to the press release.
The Website may contain links to or from other websites, over which ASLAN has no control. These linked sites are for your convenience only and you access them at your own risk.
ASLAN is not responsible for the content of the linked sites. ASLAN does not in any way endorse the linked sites.
Read about our latest product developments and partnerships, industry advances and events.